Company profile
Jasper Therapeutics, Inc.
NASDAQ:JSPRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Briquilimab | phase1 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06353971 | phase1_2 | terminated | 2024-03-18 | 2025-07-31 | Jasper Therapeutics, Inc. | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines |
| NCT06592768 | phase1 | terminated | 2024-11-26 | 2025-08-11 | Jasper Therapeutics, Inc. | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma |
| NCT06736262 | phase2 | terminated | 2024-11-26 | 2026-07-21 | Jasper Therapeutics, Inc. | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials |
| NCT06162728 | phase1_2 | completed | 2023-11-29 | 2026-07-08 | Jasper Therapeutics, Inc. | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) |
| NCT05903274 | phase1 | terminated | 2023-06-19 | 2024-10-21 | Jasper Therapeutics, Inc. | JSP191 (briquilimab) in Subjects with LR-MDS |
FDA applications (0)
No records yet.